RNAi therapeutics are revolutionizing disease treatment,
with six approved therapies primarily targeting rare genetic
disorders. As many potential disease targets still lack effective
treatments, RNAi-based therapies are becoming increasingly crucial
in biopharmaceutical research.
BOSTON, July 9, 2024
/PRNewswire/ -- "According to the latest BCC Research study, the
demand for "RNAi Technologies and Global Markets" is
estimated to increase from $2.1
billion in 2023 to reach $4.8
billion by 2029, at a compound annual growth rate (CAGR) of
14.8% from 2024 through 2029."
This report investigates the RNA interference (RNAi) technology
market, analyzing various segments such as tools and reagents,
diagnostics, therapeutics, and agriculture. BCC Research evaluates
the status of each segment, forecasts growth over the next six
years, and explores the market's drivers, restraints, challenges,
and opportunities. It includes detailed company profiles of key
players, covering their business segments, financials, product
portfolios, and recent developments. Additionally, the report
delves into emerging technologies, the regulatory landscape,
patent, and pipeline analysis, ESG developments, investment
outlook, and market deals.
The following factors drive the global market for RNAi
technology:
Increasing Prevalence of Chronic Diseases: Chronic
diseases like cancer, diabetes, cardiovascular disorders, and
neurodegenerative conditions are becoming increasingly common
around the world. RNA interference (RNAi) therapies offer a
promising approach to treating these chronic illnesses by targeting
specific genes involved in their progression. The rising number of
people affected by chronic diseases is driving the demand for
RNAi-based treatments, as they offer a new way to manage and
mitigate these conditions potentially.
Increasing Approval of RNAi Products: Regulatory
agencies, including the FDA, have recently approved several
RNAi-based drugs, such as Onpattro for hereditary
transthyretin-mediated amyloidosis and Givlaari for acute hepatic
porphyria. These approvals are significant because they validate
the safety and effectiveness of RNAi therapeutics. This regulatory
support encourages further research and investment in the field,
fostering a positive environment for the development of new
RNAi-based therapies.
Advancements in RNAi Delivery Systems: A crucial factor
for the success of RNAi therapies is the efficient delivery of RNAi
molecules to target cells. Researchers have made considerable
progress in this area, developing advanced delivery systems such as
lipid nanoparticles, polymer-based carriers, and viral vectors.
These improved delivery methods enhance the bioavailability and
tissue specificity of RNAi drugs, making them more effective in
reaching and acting on the intended cells.
Increasing Strategic Initiatives: Innovation in
RNAi-based therapies is being driven by strategic initiatives like
collaborations, partnerships, and licensing agreements among
pharmaceutical companies, biotech firms, and academic institutions.
These collaborative efforts accelerate the development and
commercialization of RNAi therapies, bringing new treatments to
market more quickly and efficiently.
Convenient Dosing: RNAi drugs often require repeated
dosing to maintain their therapeutic effects. Advances in drug
formulation and dosing regimens aim to make these treatments more
convenient for patients. Efforts to reduce the frequency of dosing
and enhance patient compliance are key factors contributing to the
growth of the RNAi therapy market, as they improve the overall
patient experience and the effectiveness of the treatments.
Request a Sample Copy of The global market for RNAi
technology Report.
Report Synopsis
Report
Metrics
|
Details
|
Base year
considered
|
2023
|
Forecast Period
considered
|
2024-2029
|
Base year market
size
|
$2.1 Billion
|
Market Size
Forecast
|
$4.8 Billion
|
Growth rate
|
CAGR of 14.8% for the
forecast period of 2024-2029
|
Segment
Covered
|
Technology, Therapeutic
Area, Delivery Method
|
Regions
covered
|
North America, Europe,
Emerging Markets
|
Key Market
Drivers
|
•
Increasing Prevalence of Chronic
Disease
•
Increasing Approval of RNAi
Products
•
Advancements in RNAi Delivery
Systems
•
Increasing Strategic
Initiatives
•
Convenient Dosing
|
Key Interesting Facts About the global market for RNAi
technology:
- RNAi technology has seen significant growth since the
approval of its first drug in 2018, marking a breakthrough after
two decades of research.
- Initially, major pharmaceutical companies like Roche,
Pfizer, and AstraZeneca were active in the field but withdrew due
to drug failures.
- Alnylam persevered and achieved the first RNAi drug approval,
revitalizing interest, and investment in the market.
- The approval of hepatomiR as an IVD diagnostic product is a
notable milestone, expanding clinical applications beyond previous
limitations.
The global market for RNAi technology report includes
in-depth data and analysis addressing the following important
queries:
1. What is the projected market size and growth rate of
the market?
The RNAi technology market is estimated to be $2.1 billion in 2023 and is forecasted to grow at
a CAGR of 14.8% to reach a value of $4.8
billion by the end of 2029.
2. What are the key factors driving the growth of the
market?
- Increasing prevalence of chronic diseases
- Increasing strategic initiatives
- Advancements in drug delivery technologies
- Increasing approvals of RNAi drugs
3. What segments are covered in the market?
The global market is segmented based on technology type into
therapeutics, diagnostics, agriculture, and reagents and tools.
Therapeutics is further segmented into rare and genetic disorders
and cardiovascular disorders and by delivery technology into
lipid-nanoparticles and conjugate delivery. The reagents and tools
are further segmented into tools, constructs, and reagents.
4. By Type, which segment will dominate the market by the
end of 2029?
Therapeutics will dominate the market by the end of 2029.
5. Which region has the highest market share in the
market?
North America holds the highest
share of the market.
Some of the Key Market Players Are:
- ALNYLAM PHARMACEUTICALS INC.
- ARROWHEAD PHARMACEUTICALS INC.
- ARBUTUS BIOPHARMA CORP.
- BAYER AG
- MERCK KGAA
- NOVARTIS AG
- NOVO NORDISK A/S
- OLIX PHARMACEUTICALS INC.
- QIAGEN
- REVVITY INC.
- SILENCE THERAPEUTICS
- SIRNAOMICS
- SYLENTIS S.A.
- SWITCH THERAPEUTICS
- THERMO FISHER SCIENTIFIC INC.
Browse More Related Reports:
Oligonucleotides: Global Markets: This report covers the
global market for oligonucleotide synthesis, focusing on four main
product types: oligonucleotide drugs, synthesized oligos, equipment
and reagents, and services. The market is segmented by application
into research diagnostics and therapeutics. Geographically, the
report divides the market into North
America, Europe,
Asia-Pacific, and the Rest of the
World (RoW). It provides market estimates based on data from 2022
and includes forecasts for 2023 through 2028. Additionally, the
report discusses approved drugs, the oligonucleotide synthesis
process, innovative research, market opportunities, and profiles of
leading companies in the industry.
RNAi Drug Delivery: Technologies and Global Markets: This
report categorizes the market for nucleic acid drugs by type,
focusing on major product segments like conjugated and encapsulated
drugs. Non-viral vectors for encapsulation are further divided into
polymers, lipids, and other materials such as inorganic substances
and hybrid systems. The market segmentation also includes molecule
types, delivery modes, and therapeutic areas. Applications are
divided into therapeutic and research-based categories. The report
covers markets in North America,
Europe, Asia-Pacific, and the Rest of the World
(RoW).
Directly Purchase a copy of the
report with BCC Research.
For further information or to make a purchase, please get in
touch with info@bccresearch.com.
About BCC Research
BCC Research provides objective, unbiased measurement and
assessment of market opportunities with detailed market research
reports. Our experienced industry analysts' goal is to help you
make informed business decisions, free of noise and hype.
Contact Us
Corporate HQ: 50 Milk St. Ste 16, Boston, MA 02109, USA
Email: info@bccresearch.com,
Phone: +1 781-489-7301
For media inquiries, email press@bccresearch.com or visit
our media page for access to our market research library.
Data and analysis extracted from this press release must be
accompanied by a statement identifying BCC Research LLC as the
source and publisher.
Logo:
https://mma.prnewswire.com/media/2183242/BCC_Research_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/rnai-technologies-a-new-era-in-global-chronic-disease-treatment-302191923.html
SOURCE BCC Research LLC